This supports preclinical optimisation and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal is to accelerate the optimisation and development of promising small molecule and biologic hits or leads towards clinical trials. Applicants must have a promising hit or lead, robust biological rationale for the intended approach, and identified assays for optimisation of the agent. The scope of this programme includes optimisation and early development activities, investigational new drug-enabling studies, and assembly of IND application.
Funding & Duration
Each project may receive up to USD $500,000 (approx. AUD $692,000) per year for a period of two years in the UG3 exploratory phase, and up to USD $1.5M (approx. AUD $2.08M) per year in the UH3 developmental phase.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Date
- Applications must be submitted for internal review by 21 December 2018
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review